olmesartan has been researched along with aluminum hydroxide, magnesium hydroxide, drug combination in 1 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (aluminum hydroxide, magnesium hydroxide, drug combination) | Trials (aluminum hydroxide, magnesium hydroxide, drug combination) | Recent Studies (post-2010) (aluminum hydroxide, magnesium hydroxide, drug combination) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 253 | 100 | 17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kirch, W; Laeis, P; Püchler, K | 1 |
1 other study(ies) available for olmesartan and aluminum hydroxide, magnesium hydroxide, drug combination
| Article | Year |
|---|---|
The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.
Topics: Administration, Oral; Adult; Aluminum Hydroxide; Biological Availability; Blood; Digoxin; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Humans; Hydrolysis; Imidazoles; Injections, Intravenous; Magnesium Hydroxide; Male; Olmesartan Medoxomil; Tetrazoles; Warfarin | 2001 |